USP1 is a topical target for cancer therapeutics [172], particularly given its synthetic lethality with BRCA1 [167], and it is possible that pharmacological inhibition of USP1 may lead to USP1 trapping in addition to abrogation of its DUB activity, and therefore may explain some of the effects seen. The gene discussed is ZUP1; the disease is cancer.